No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LIPO Lipella Pharmaceuticals
- 0.711
- +0.003+0.35%
Close Apr 26 16:00 ET
- 0.720
- +0.009+1.27%
Post 16:11 ET
5.01MMarket Cap-923P/E (TTM)
0.739High0.711Low4.34KVolume0.725Open0.709Pre Close3.14KTurnover0.10%Turnover RatioLossP/E (Static)7.04MShares2.71052wk High1.59P/B3.02MFloat Cap0.64052wk Low--Dividend TTM4.25MShs Float7.720Historical High--Div YieldTTM3.99%Amplitude0.640Historical Low0.723Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Lipella Pharmaceuticals Expands Its Advisory Board to Include Oncology Expertise
Express News | Maxim Group Initiates Coverage On Lipella Pharmaceuticals With Buy Rating, Announces Price Target of $2
Lipella Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 185.92% Maxim Group → $2 Initiates Coverage On → Buy
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
Express News | Lipella Pharmaceuticals Announces FDA Type C Meeting For LP-10 For Hemorrhagic Cystitis; Co. Expects To Meet With FDA May 21
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with
Comments
Update
$Lipella Pharmaceuticals(LIPO.US$ Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
1
1
Insider buy
$Lipella Pharmaceuticals(LIPO.US$ 10% Shareholder Kaufman Jonathan H purchased 55,000 shares of Common Stocks on Mar 18, 19, 2024 at an average price of $0.8264 for a total value of $45,451.5.
1
13
New drug application
$Lipella Pharmaceuticals(LIPO.US$ Small float and FDA approval for trials to begin. Im in at .78. Long hold of 3 months for 200% profit.
5
2
3
Nice
$Lipella Pharmaceuticals(LIPO.US$ Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
3 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
3 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
TrytosaveabitOP : Co. Expects To Meet With FDA May 21